Obesity linked with high rates of prostate Ca screening

Article

Obesity appears to be associated with higher rates of prostate cancer screening across all races and ethnicities, recent study findings indicate.

Obesity appears to be associated with higher rates of prostate cancer screening across all races and ethnicities, recent study findings indicate.

"Numerous studies have suggested that obesity constitutes an obstacle to cancer screening, but a deeper examination also considering the role of race/ethnicity and gender in the equation has not been done before," said lead author Heather Bittner Fagan, MD, MPH, of Thomas Jefferson University, Philadelphia, and Christiana Care Health System, Wilmington, DE. "A greater understanding of the relationship between cancer screening and obesity, race/ethnicity and gender can also help explain the association between obesity and increased cancer mortality."

Prostate cancer screening levels were consistently shown to increase with weight. In three of four studies, obese men were more likely to receive a PSA test for prostate cancer screening than their normal-weight peers. This unique finding seems to remain across race/ethnicity differences.

"This could be explained by differences in access and utilization of health care; as weight increases, so do other co-morbid conditions, making heavier men higher users of health care and perhaps more encouraged to be tested by their health care provider," said co-author Richard Wender, MD, of Thomas Jefferson University.

"Screening behaviors can vary by ethnicity/race and gender, but more research is needed to create a comprehensive understanding of obesity and cancer screening in race-gender subgroups," Drs. Fagan and Wender said.

Results from the study were published online in the Journal of Obesity (Dec. 15, 2011).

Go back to this issue of Urology Times eNews.

Related Videos
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.